JACOBS LEVY EQUITY MANAGEMENT, INC - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 105 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
JACOBS LEVY EQUITY MANAGEMENT, INC ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q4 2022$236,577
-18.7%
202,202
-21.5%
0.00%0.0%
Q3 2022$291,000257,4610.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q3 2022
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,935,485$41,223,8723.66%
Raffles Associates 1,587,739$1,873,5322.48%
Defender Capital, LLC. 5,184,510$6,117,7222.22%
Prescott General Partners LLC 1,851,851$2,185,1840.14%
DCF Advisers, LLC 82,751$97,6460.05%
Beirne Wealth Consulting Services, LLC 45,000$63,4500.05%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 781,766$922,4840.02%
Fort Sheridan Advisors LLC 83,931$99,0390.02%
MAI Capital Management 954,688$1,126,5320.02%
Piscataqua Savings Bank 12,499$14,6230.01%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders